These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10791274)

  • 1. [Usefulness of fluorine-18 fluoro-2-deoxyglucose positron emission tomography for diagnosis and therapy assessment of cardiac sarcoidosis].
    Ishida Y; Nakatani S; Tachibana T
    J Cardiol; 2000 Apr; 35(4):301-4. PubMed ID: 10791274
    [No Abstract]   [Full Text] [Related]  

  • 2. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques.
    Pandya C; Brunken RC; Tchou P; Schoenhagen P; Culver DA
    Eur Respir J; 2007 Feb; 29(2):418-22. PubMed ID: 17264327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in radionuclide imaging of cardiac sarcoidosis.
    Kouranos V; Wells AU; Sharma R; Underwood SR; Wechalekar K
    Br Med Bull; 2015 Sep; 115(1):151-63. PubMed ID: 26311504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of follow-up gallium single-photon emission computed tomography and fluorine-18-fluorodeoxyglucose positron emission tomography to predict the deterioration of a patient with cardiac sarcoidosis.
    Kaku B; Kanaya H; Horita Y; Uno Y; Yamazaki T; Fujita T; Ohka T
    Circ J; 2004 Aug; 68(8):802-5. PubMed ID: 15277743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Images in cardiovascular medicine. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy.
    Tadamura E; Yamamuro M; Kubo S; Kanao S; Hosokawa R; Kimura T; Kita T; Togashi K
    Circulation; 2006 May; 113(20):e771-3. PubMed ID: 16717157
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis.
    Ishimaru S; Tsujino I; Sakaue S; Oyama N; Takei T; Tsukamoto E; Tamaki N; Nishimura M
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):234-5. PubMed ID: 16315788
    [No Abstract]   [Full Text] [Related]  

  • 7. (18)F-FDG PET/CT for the assessment of myocardial sarcoidosis.
    Skali H; Schulman AR; Dorbala S
    Curr Cardiol Rep; 2013 May; 15(5):352. PubMed ID: 23504346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Corticosteroid Dose and Duration on 18-Fluorodeoxyglucose Positron Emission Tomography in Cardiac Sarcoidosis.
    Okada DR; Saad E; Wand AL; Griffin JM; Kasper EK; Chen EH; Chrispin J; Tandri H; Solnes LB; Gilotra NA
    JACC Cardiovasc Imaging; 2020 May; 13(5):1280-1282. PubMed ID: 31954655
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnostic Value of PET in Cardiac Sarcoidosis.
    Smedema JP; van Kroonenburgh MJ; Snoep G; Bekkers SC; Gorgels AP
    J Nucl Med; 2004 Nov; 45(11):1975. PubMed ID: 15534072
    [No Abstract]   [Full Text] [Related]  

  • 10. SPECT imaging with Tl-201 and Ga-67 in myocardial sarcoidosis.
    Kurata C; Sakata K; Taguchi T; Fukumoto Y; Miyata H; Aoshima S; Yamazaki N
    Clin Nucl Med; 1990 Jun; 15(6):408-11. PubMed ID: 2354580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?
    Alavi A; Buchpiguel CA; Loessner A
    J Nucl Med; 1994 Oct; 35(10):1650-2. PubMed ID: 7931665
    [No Abstract]   [Full Text] [Related]  

  • 12. Early detection of cardiac sarcoid lesions with (18)F-fluoro-2-deoxyglucose positron emission tomography.
    Ohira H; Tsujino I; Sato T; Yoshinaga K; Manabe O; Oyama N; Nishimura M
    Intern Med; 2011; 50(11):1207-9. PubMed ID: 21628936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac sarcoidosis: the complementary role of 18F-FDG PET and MRI.
    Van Schandevyl S; Waterschoot R; De Vos N; Devos D; Goethals I
    J Cardiovasc Med (Hagerstown); 2020 Apr; 21(4):335-336. PubMed ID: 31809284
    [No Abstract]   [Full Text] [Related]  

  • 14. [Fluorodeoxyglucose-positron emission tomographic findings in a patient with pacing failure].
    Iwado Y; Shinomiya K; Ohmori K; Kohno M; Senda S
    J Cardiol; 2005 Apr; 45(4):173-5. PubMed ID: 15875540
    [No Abstract]   [Full Text] [Related]  

  • 15. Malfunctioned cardiac resynchronization therapy attributed to acute exacerbation of cardiac sarcoidosis.
    Ikeda S; Ohtani K; Uwatoku T; Higo T
    Eur Heart J; 2016 Sep; 37(33):2613. PubMed ID: 27225198
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis.
    Tahara N; Tahara A; Nitta Y; Kodama N; Mizoguchi M; Kaida H; Baba K; Ishibashi M; Hayabuchi N; Narula J; Imaizumi T
    JACC Cardiovasc Imaging; 2010 Dec; 3(12):1219-28. PubMed ID: 21163450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer or inflammation? A Holy Grail for nuclear medicine.
    Larson SM
    J Nucl Med; 1994 Oct; 35(10):1653-5. PubMed ID: 7931666
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnosis of cardiac sarcoidosis through mismatched defects seen on N-13 NH3/F-18 FDG cardiac PET.
    Chen S; Bokhari S
    Clin Nucl Med; 2011 Dec; 36(12):1156-7. PubMed ID: 22064101
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluorodeoxyglucose Myocardial Accumulation to Assess Response to Immunosuppressive Treatment in Cardiac Sarcoidosis.
    Cooper LT; Reddy P
    JACC Cardiovasc Imaging; 2024 Jan; 17(1):59-61. PubMed ID: 37656116
    [No Abstract]   [Full Text] [Related]  

  • 20. PET/CT Evaluation of Cardiac Sarcoidosis.
    Bois JP; Muser D; Chareonthaitawee P
    PET Clin; 2019 Apr; 14(2):223-232. PubMed ID: 30826020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.